Canada - English - Health Canada

elvium life sciences - dorzolamide (dorzolamide hydrochloride) - solution - 2% - dorzolamide (dorzolamide hydrochloride) 2% - carbonic anhydrase inhibitors

Canada - English - Health Canada

elvium life sciences - dorzolamide (dorzolamide hydrochloride) - solution - 2% - dorzolamide (dorzolamide hydrochloride) 2% - carbonic anhydrase inhibitors

United States - English - NLM (National Library of Medicine)

akorn - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1), timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - dorzolamide 20 mg in 1 ml - cosopt® is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target iop determined after multiple measurements over time). the iop-lowering of cosopt administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day [see clinical studies (14)]. cosopt is contraindicated in patients with bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease [see warnings and precautions (5.1)]. cosopt is contraindicated in patients with sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, and cardiogenic shock [see warnings and precautions (5.2)]. cosopt is contraindicated in patients who are hypersensitive to any component of this product [see warnings and precautions (5.3)]. teratogen

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1) - dorzolamide 20 mg in 1 ml - trusopt® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. trusopt is contraindicated in patients who are hypersensitive to any component of this product [see warnings and precautions (5.1)] . risk summary there are no adequate and well-controlled studies in pregnant women with trusopt. dorzolamide caused fetal vertebral malformations when administered orally to rabbits at 2.5 mg/kg/day (37 times the clinical exposure). dorzolamide administered during the period of organogenesis was not teratogenic in rabbits dosed up to 1 mg/kg/day (15 times the clinical exposure). dorzolamide hydrochloride administered orally to rats during late gestation and lactation caused growth delays in offspring at 7.5 mg/kg/day (52 times the clinical exposure). growth was not delayed at 1 mg/kg/day (8.0 times the clinical exposure). the background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general populati

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1), timolol maleate (unii: p8y54f701r) (timolol - unii:817w3c6175) - dorzolamide 20 mg in 1 ml - cosopt is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target iop determined after multiple measurements over time). the iop-lowering of cosopt b.i.d. was slightly less than that seen with the concomitant administration of 0.5% timolol b.i.d. and 2.0% dorzolamide t.i.d. (see clinical pharmacology, clinical studies). cosopt is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. please follow these instructions carefully when using cosopt. use cosopt as prescribed by your doctor. - if you use other topically applied ophthalmic medications, they should be administered at lea

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - dorzolamide hydrochloride - eye drops - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - dorzolamide hydrochloride; timolol maleate - eye drops - 20mg/1ml ; 5mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - dorzolamide hydrochloride; timolol maleate - eye drops - 20mg/1ml ; 5mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - dorzolamide; timolol - eye drops, solution - 20 mg/ml+5 milligram(s)/millilitre - beta blocking agents1); timolol, combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

bausch + lomb ireland limited - dorzolamide hydrochloride; timolol maleate - eye drops, solution - 20mg/ml+5 milligram(s)/millilitre - beta blocking agents1); timolol, combinations